# Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

> **NCT07502495** · PHASE2 · RECRUITING · sponsor: **Biomea Fusion Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** icovamenib 100mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07502495
- **Lead sponsor:** Biomea Fusion Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2027-06
- **Final completion:** 2027-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502495, "Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07502495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*